Journals / Marmara Medical Journal / 2019 / Cilt: 32 - Sayı: 1

Investigation of the relationship between insulin resistance and neuropeptide Y levels in polycystic ovary syndrome

Polikistik over sendromunda insülin rezistansı ve nöropeptid Y düzeyleri arasındaki ilişkinin araştırılması

Pages
1–6
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: No correlation dedected between insülin resistance and NPY levels but NPY levels were high in overweight PCOS patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of study is to investigate the relationship between neuropeptide Y (NPY) and insulin resistance which is important in the pathogenesis of poliycstic ovary syndrome (PCOS).
📊
Key Findings & Data:Material and Methods: This study was conducted between May 2012 and May 2013.
💡
Conclusion & Impact:Conclusion: No correlation dedected between insülin resistance and NPY levels but NPY levels were high in overweight PCOS patients.
🔬Design:Modeling & Simulation
📍Scope:2012 Verileri
⚙️Variables:Polikistik over sendromu · İnsülin rezistansı · Nöropeptid Y

Abstract

Objective: The aim of study is to investigate the relationship between neuropeptide Y (NPY) and insulin resistance which is important in the pathogenesis of poliycstic ovary syndrome (PCOS). Material and Methods: This study was conducted between May 2012 and May 2013. The study included 45 patients with PCOS and 44 healthy controls at productive age. Insulin, fasting blood sugar, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactine, testestorone, dehydroepiandrosterone sulfate (DHEA-S), thyroid stimulating hormone (TSH), cortisole, estradiol, NPY levels were measured at early follicular phase in patients with PCOS while insulin, fasting blood sugar, prolactine, DHEA-S, TSH, cortisole, 17-OH progesterone levels were measured in control group. Homeostatic model assessment for insulin resistance (HOMA-IR) scores were calculated and antrepometric measures recorded. Pelvic ultrasonography was performed. Results: Fasting insulin levels and HOMA-IR scores showed insulin resistance to be higher in obese patients with PCOS than healthy control subjects and patients with normal weight PCOS. NPY levels found to be higher in obese-overweight patients with PCOS than healthy control subjects and patients with normal weight but it was not statistically significant (P>0.05). NPY levels did not differ in patients with and without insulin resistance. Conclusion: No correlation dedected between insülin resistance and NPY levels but NPY levels were high in overweight PCOS patients.

Özet

Amaç: Çalışmanın amacı, polikistik over sendromu (PKOS)patogenezinde önemli yeri olan nöropeptid Y (NPY) ve insülindirenci arasındaki ilişkinin araştırılmasıdır.Gereçler ve Yöntemler: Bu çalışma Mayıs 2012 ve Mayıs 2013tarihleri arasında yapılmıştır. Çalışmaya doğurganlık çağındaki 45PKOS hastası ve 44 sağlıklı kontrol grubu dahil edilmiştir. PKOSgrubuna erken foliküler fazda insulin, açlık kan şekeri, folikülstimüle edici hormon (FSH), luteize edici hormon (LH), prolaktin,testesteron, dehidroepiandrosteron sülfat (DHEA-S), tiroidstimüle edici hormon (TSH), kortizol, östrodiol ve NPY düzeyleribakılırken, kontrol grubuna insülin, açlık kan şekeri, prolaktin,DHEA-S, TSH, kortizol, 17-OH progesteron düzeyleri incelendi.Homeostatik model insulin direnci değerlendirme (HOMA-IR)testi skorları hesaplandı ve antropometrik ölçümler kaydedildi.Pelvik ultrasonografi yapıldı.Bulgular: İnsulin direncini gösteren açlık kan insülin düzeyive HOMA-IR skoru, obez PKOS grubunda normal kilolu PKOSve kontrol grubuna göre yüksek bulundu. NPY düzeyleri obezyüksekkilolu PKOS grubunda normal kilolu PKOS ve kontrolgrubuna göre yüksek bulundu ancak istatistiksel olarak anlamlıdeğildi (P>0,05). NPY düzeyleri insülin rezistansı olan ve olmayanhastalar arasında değişiklik göstermedi.Sonuç: İnsülin rezistansı ve NPY düzeyleri arasındakorelasyon saptanmadı ancak NPY düzeyleri, kilolu PCOShastalarında yüksekti.

🔖

Cite This Article

KÖŞECİ, T., KAYA, Ö. E., HAKSÖYLER, V., YILDIRIM, D. D., SEZER, K. (2019). Investigation of the relationship between insulin resistance and neuropeptide Y levels in polycystic ovary syndrome. Marmara Medical Journal, Cilt: 32 - Sayı: 1, 1–6. https://ajindex.com/articles/284274

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005
  2. doi:10.1056/NEJM200.506.303522620 2. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol Rev 2004
  3. doi:10.1046/j.1365- 2265.2003.01842.x 3. Kayaalp O. Tıbbi Farmakoloji. Cilt:2 9. Baskı. Ankara: Hacettepe Taş Kitabevi, 2000. 4. Herzog, H. Neuropeptide Y and energy homeostasis: insights from Y receptor knockout models. Eur J Pharmacol 2003
  4. doi:10.1016/j.ejphar.2003.08.089 5. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009
  5. doi: 10.1016/j.fertnstert.2008.06.035. 6. The Rotterdam ESHRE/ASRM-Sponsered PCOS Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004
  6. doi:10.1016/j. fertnstert.2003.10.004 7. Bayram F, Ünlühızarcı K, Kelestimur F. Potential utility of insulin sensitizers in the treatment of polycystic ovary syndrome. Treat Endocrinol 2002
  7. doi:10.2165/00024.677.200201010-00005 8. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997
  8. doi:10.1210/ edrv.18.6.0318 9. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 1983
  9. doi:10.1016/0002- 9378(83)90091-1 10. Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocr Rev 1987
  10. doi:10.1210/edrv-8-2-132 11. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991
  11. doi:10.1210/edrv-12-1-3 12. Tsilchorozidou T, Overton C, Convay SG. The Pathophysiology of polycystic ovary syndrome. Clin Endocrinol 2004
  12. doi:10.1046/j.1365-2265.2003.01842.x 13. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity in polycystic ovary syndrome. Diabetes 1989
  13. doi:10.2337/diab.38.9.1165 14. Dunaif A, Segal KR, Shelley DR, et al. Evidence for dinstinctive and intrinsic defect in insulin action in polycystic ovary syndrome. Diabetes 1992
  14. doi:10.2337/diab.41.10.1257 15. Dunaif A, Kandarakis DE. New perspectives in polycystic ovary syndrome. Trends Endocrinol Metab